Similarly, Zhang and colleagues recently proposed that the cholesterol-lowering medication lomitapide acts as an anti-MM agent, overcoming bortezomib resistance by inducing excessive DRP1-mediated mitophagy and, subsequently, mitochondrial damage [117]. Here, DNM1L is linked to Miyoshi myopathy.